Search for 'an,phr: 433' with limit(s): 'au:Castellano, Daniel'

Sequential treatments in hereditary leiomyomatosis and renal cell carcinoma (HLRCC): Case report and review of the literature.

By De Velasco, Guillermo | Muñoz, César | Sepúlveda Sánchez, Juan Manuel | Castellano, Daniel. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2015 . 9(3-4):E243-6. , Formato Vancouver: de Velasco G, Munoz C, Sepulveda JM, Castellano D. Sequential treatments in hereditary leiomyomatosis and renal cell carcinoma (HLRCC): Case report and review of the literature. Can Urol Assoc J. 2015 Mar-Apr;9(3-4):E243-6.

Place Hold on Sequential treatments in hereditary leiomyomatosis and renal cell carcinoma (HLRCC): Case report and review of the literature.

Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies.

By Castellano, Daniel | Sepúlveda Sánchez, Juan Manuel. Expert opinion on drug safety, 2014 . 13(4):497-510 , Formato Vancouver: Bracarda S, Castellano D, Procopio G, Sepúlveda JM, Sisani M, Verzoni E et al. Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies. Expert Opin Drug Saf. 2014 Apr;13(4):497-510. doi: 10.1517/14740338.2014.888413. .

Place Hold on Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies.

The role of pharmacogenomics in metastatic renal cell carcinoma.

By Castellano, Daniel | Sepúlveda Sánchez, Juan Manuel. Cancer and Metastasis Reviews, 2012 . 146(3):117-20. , Formato Vancouver: Castellano D, Virizuela JA, Cruz J, Sepulveda JM, Sáez MI, Paz-Ares L. The role of pharmacogenomics in metastatic renal cell carcinoma. Cancer Metastasis Rev. 2012 Sep;31 Suppl 1:S29-32.

Place Hold on The role of pharmacogenomics in metastatic renal cell carcinoma.

Therapeutic management of chronic lymphocytic leukaemia: state of the art and future perspectives

By Castellano, Daniel | Cortés-Funes Castro, Hernán | García Escobar, Ignacio | Sepúlveda Sánchez, Juan Manuel. Critical Reviews in Oncology/Hematology, 2011 . 80(1):100-113. , Formato Vancouver: García-Escobar I, Sepúlveda J, Castellano D, Cortés-Funes H. Therapeutic management of chronic lymphocytic leukaemia: state of the art and future perspectives. Crit Rev Oncol Hematol. 2011;80(1):100-13.

Place Hold on Therapeutic management of chronic lymphocytic leukaemia: state of the art and future perspectives

Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients

By Castellano, Daniel | Sepúlveda Sánchez, Juan Manuel. Expert Opinion on Pharmacotherapy, 2011 . 12(16):2433-2439. , Formato Vancouver: Castellano D, González-Larriba JL, Antón-Aparicio LM, Cassinello J, Grande E, Esteban E, et al. Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients. Expert Opin Pharmacother. 2011 Nov;12(16):2433-9.

Place Hold on Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients

The role of RANK-ligand inhibition in cancer: The story of denosumab

By Castellano, Daniel | Cortés-Funes Castro, Hernán | García Escobar, Ignacio | Sepúlveda Sánchez, Juan Manuel | Rodríguez Antolín, Alfredo. Oncologist, 2011 . 16(2):136-145. , Formato Vancouver: Castellano D, Sepúlveda JM, García Escobar I, Rodriguez Antolín A, Sundlöv A, Cortés-Funes H. The role of RANK-ligand inhibition in cancer: the story of denosumab. Oncologist. 2011;16(2):136-45.

Place Hold on The role of RANK-ligand inhibition in cancer: The story of denosumab